Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

New Device Retrieves Circulating Tumor Cells Without Biochemical Labeling

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Image: The ClearCell FX System for retrieval of circulating tumor cells. (Photo courtesy of Clearbridge BioMedics).
Image: The ClearCell FX System for retrieval of circulating tumor cells. (Photo courtesy of Clearbridge BioMedics).
A new device has been developed for improved cancer diagnosis and monitoring, without biochemical markers, that uses a noninvasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalized medication, and treatment monitoring.

Clearbridge BioMedics (Singapore) introduces its “ClearCell FX System,” a new generation cancer diagnostic and monitoring device that rapidly detects and isolates intact circulating tumor cells (CTCs) from small quantities of patient blood samples. The ClearCell FX System technology separates and isolates cells by using novel inertia focusing spiral microfluidics in the single-use “CTChip FR.” This enables the continuous label-free separation—without biochemical labels—of CTCs from blood cells. The larger and denser CTCs are separated from other blood cells within the spiral biochip due to biomechanical differences and are then focused into an enriched cell “stream.” These cell streams are channeled and collected into an enriched sample, which can be used for pathology diagnostic tests such as mutation testing for targeted therapies. The isolated CTCs can be stained for identification and enumeration, or retrieved for further molecular analysis.

“This has been a collaborative merging of our extensive experience in diagnostic device development and Clearbridge BioMedics’ expertise in cancer research and diagnostics—and it’s led to breakthrough technology that will have a huge impact on a lot of people’s lives,” said John Pritchard, head of diagnostics at Cambridge Consultants of Altran; “Our systems engineering approach, coupled with our skills in fluidics, software, and compliance, has enabled us to work quickly and efficiently with Clearbridge BioMedics—even though we are thousands of miles apart.” Clearbridge BioMedics also collaborated with the National University of Singapore and the Singapore-MIT Alliance for Research and Technology Center.

The new system, designed for both research and diagnostics applications, will be undergoing regulatory approval in the US and Europe. “Once approved, it will be one of the world’s first label-free CTC enrichment systems for diagnostic use. Clearbridge BioMedics believes this system will be an ideal companion diagnostic system that complements various cancer therapies,” said Johnson Chen, cofounder and managing director of Clearbridge BioMedics.

Related Links:

Clearbridge BioMedics
Cambridge Consultants



view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Biopharmaceutical Partners Seek Alternatives to Glucocorticoid Steroid Drugs

Collaboration between American and Japanese biopharmaceutical companies is expected to lead to the development of a new class of small molecule drugs for treatment of hematological and inflammatory diseases. Gencia LLC (Charlottesville, VA, USA) and Takeda Pharmaceutical Company Ltd. (Osaka, Japan) announced the formation... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.